BIOCRYST PHARMACEUTICALS INC (BCRX)
US09058V1035 - Common Stock
BioCryst to Report Second Quarter 2024 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
Interesting BCRX Put And Call Options For August 16th
ORLADEYO® (berotralstat) Approved in Peru
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis...
Top Buys by Top Brass: Chief Financial Officer Doyle's $202.2K Bet on BCRX
Wednesday Sector Leaders: General Contractors & Builders, Biotechnology Stocks
Bargain Hunters Take Note: Insider Cluster-Buying At BCRX
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data on oral,...
ORLADEYO® (berotralstat) Approved in Mexico
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission...
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)
RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on...
January 2026 Options Now Available For BioCryst Pharmaceuticals (BCRX)
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally.
BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2024.
BCRX Stock Earnings: BioCryst Pharma Beats EPS, Beats Revenue for Q1 2024
BCRX stock results show that BioCryst Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
BCRX Stock Earnings: BioCryst Pharma Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioCryst Pharma (NASDAQ:BCRX) just reported results for the first quarter of 20...
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
BioCryst Pharmaceuticals Enters Oversold Territory (BCRX)
First Week of BCRX December 20th Options Trading
BioCryst to Report First Quarter 2024 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
These penny stocks offer triple digit returns to investors right now but not many investors are aware of them.
BioCryst Pharmaceuticals files for a mixed securities shelf (NASDAQ:BCRX)
BioCryst Pharmaceuticals (BCRX) has filed a prospectus for a mixed shelf offering, but it is not an offer to sell securities.
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2023.
BioCryst Pharmaceuticals reports Q4 results (NASDAQ:BCRX)
BioCryst Pharmaceuticals reported Q4 financial results, with non-GAAP EPS missing by $0.05 and revenue beating estimates.
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be...